Details for Patent: 7,871,607

Title:	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
Abstract:	The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
Inventor(s):	Bookbinder; Louis H. (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Del Mar, CA)
Assignee:	Halozyme, Inc. (San Diego, CA)
Filing Date:	Feb 23, 2005
Application Number:	11/065,716
Claims:	1. A method for increasing the diffusion of an antibiotic in a tissue of a subject, comprising: administering to the tissue of a subject a composition containing a hyaluronidase glycoprotein in an amount sufficient to increase diffusion of the antibiotic, wherein: the hyaluronidase glycoprotein consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO: 1, or contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO: 1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO: 1; the glycoprotein contains at least one sugar moiety that is covalently attached to an asparagine (N) residue of the polypeptide; and the glycoprotein is active at neutral pH; and administering to the tissue an antibiotic. 2. The method of claim 1, wherein the antibiotic is a small molecule or is a protein. 3. The method of claim 1, wherein the antibiotic is a polypeptide. 4. The method of claim 1, wherein the antibiotic agent or combination of agents is selected from among Aminoglycosides; Amphenicols; Ansamycins; Carbacephems; Carbapenems; Cephalosporins; Cephems; Cephamycins; Clavams; Cyclic lipopeptides; Diaminopyrimidines; Ketolides; Lincosamides; Macrolides; Monobactams; Nitrofurans; Oxacephems; Oxazolidinones; Penems; thienamycins; beta-lactams; Penicillins; Polypeptides antibiotics; Quinolones; Sulfonamides; Sulfones; Tetracyclines; Clofoctols; Fusidic acids; Hexedines; Methenamines; Nitrofurantoins; Nitroxolines; Ritipenems; Taurolidines and Xibomols. 5. The method of claim 1, wherein the glycoprotein is administered at a dose between 1 and 5,000,000 turbidity reducing units (TRU). 6. The method of claim 1, wherein the glycoprotein consists of the sequence of amino acids set forth in SEQ ID NO. 4. 7. The method of claim 1, wherein the tissue is skin, the subcutaneous layer of the skin or a muscle. 8. The method of claim 1, wherein the glycoprotein is modified with a polymer. 9. The method of claim 8, wherein the polymer is PEG or dextran. 10. The method of claim 1, wherein the glycoprotein is encoded by a nucleic acid molecule that encodes amino acids 36-482 of SEQ ID NO: 1. 11. The method of claim 1, wherein the hyaluronidase glycoprotein in the composition consists of the sequence of amino acids set forth as amino acids 36-482 of SEQ ID NO. 1. 12. The method of claim 1, wherein the sequence of amino acids residues of the glycoprotein is selected from among the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 and 36-483 in SEQ ID NO: 1. 13. The method of claim 1, wherein the antibiotic agent is selected from among Ampicillins, Azithromycins, Becaplermins, Cefazolins, Cefepimes, Cefotetans, Ceftazidimes, Ceftriaxones, Clavulanic Acids, Clindamycins, Gatifloxacins, Levofloxacins, Meropenems, Piperacillins, Sulbactams, Tazobactams, Ticarcillins, and Vancomycins. 14. The method of claim 13, wherein the glycoprotein is modified with a polymer. 15. The method of claim 14, wherein the polymer is PEG or dextran. 16. The method of claim 13, wherein the sequence of amino acid residues of the glycoprotein is set forth in SEQ ID NO: 4. 17. The method of claim 13, wherein the glycoprotein is encoded by a nucleic acid molecule that encodes amino acids 36-482 of SEQ ID NO: 1. 18. The method of claim 13, wherein the hyaluronidase glycoprotein in the composition consists of the sequence of amino acid residues 36-482 of SEQ ID NO. 1. 19. The method of claim 13, wherein the sequence of amino acids residues of the glycoprotein is selected from among the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 and 36-483 in SEQ ID NO: 1. 20. The method of claim 1, wherein the glycoprotein is administered separately or is co-formulated with the antibiotic. 21. The method of claim 1, wherein the glycoprotein is administered prior to, simultaneously with or following administration of the antibiotic. 22. The method of claim 1, wherein the glycoprotein and antibiotic are co-formulated and administered as an aerosol. 23. The method of claim 1, wherein the antibiotic is selected from among a Aclacinomycins; Aclarubicins; Actinomycins; Adriamycins; Alatrofloxacins; Ambomycins; Ametantrones; Amikacins; Anthramycins; Asperlins; Azotomycins; Bacitracins; Bleomycins; Cactinomycins; Capreomycins; Carubicins; Cefotaximes; Cefoxitins; Ceftizoximes; Cefuroximes; Chloramphenicols; Chromomycins; Ciprofloxacins; Cirolemycins; Dactinomycins; Daunorubicins; Daunomycins; Doxorubicins; Doxorubicin liposomals; Doxycyclines; Duazomycins; Elsamitrucins; Epirubicins; Ertapenems; Erythromycins; Esorubicins; Fepirubicins; Fostriecins; Galarubicins; Gentamicins; Guamecyclines; Idarubicins; Kanamycins; Levamisoles; Lincomycins; Mithramycins; Minocyclines; Mitocarcins; Mitocromins; Mitomalcins; Mitomycin C; Mitoxantrones; Nafcillins; Nemorubicins; Nogalamycins; Olivomycins; Oxacillinsl ; Oxytetracyclines; Peliomycins; Peplomycins; Pirarubicins; Plicamycins; Polymyxin b; Porfiromycins; Puromycins; Pyrazofurins; Rifampins; Rufocromomycins; Sabarubicins; Sparsomycins; Streptonigrins; Spectinomycins; Streptomycins; Streptozocins; Talisomycins; Tubercidins; Tobramycins; Valrubicins; Vinblastines; Vincristines; Xanthomycin A; Zinostatins; and Zorubicins. 24. The method of claim 23, wherein the glycoprotein is modified with a polymer. 25. The method of claim 24, wherein the polymer is PEG or dextran. 26. The method of claim 23, wherein the sequence of amino acid residuess of the glycoprotein is set forth in SEQ ID NO: 4. 27. The method of claim 23, wherein the glycoprotein is encoded by a nucleic acid molecule that encodes amino acids 36-482 of SEQ ID NO: 1. 28. The method of claim 23 , wherein the hyaluronidase glycoprotein in the composition consists of the sequence of amino acids 36-482 of SEQ ID NO. 1. 29. The method of claim 23, wherein the sequence of amino acid residuess of the glycoprotein is selected from among the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 and 36-483 in SEQ ID NO: 1. 30. The method of claim 1, wherein the hyaluronidase glycoprotein is produced in and secreted from a mammalian cell. 31. The method of claim 30, wherein the mammalian cell is a CHO cell. 32. The method of claim 1, wherein the glycoprotein and antibiotic are co-formulated and administered as a liquid solution.